Farabi Pharmaceutical (XTEH:DFRB1) Operating Margin %: 0.00% (As of . 20)


What is Farabi Pharmaceutical Operating Margin %?

Farabi Pharmaceutical XTEH:DFRB1 Operating Margin % is 0.00% as of . 20.

Operating Margin % is calculated as Operating Income divided by its Revenue. Farabi Pharmaceutical's Operating Income for the three months ended in . 20 was IRR0.00 Mil. Farabi Pharmaceutical's Revenue for the three months ended in . 20 was IRR0.00 Mil. Therefore, Farabi Pharmaceutical's Operating Margin % for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Farabi Pharmaceutical's Operating Margin % or its related term are showing as below:


XTEH:DFRB1's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.45
* Ranked among companies with meaningful Operating Margin % only.

Farabi Pharmaceutical's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Farabi Pharmaceutical's Operating Income for the three months ended in . 20 was IRR0.00 Mil.


Farabi Pharmaceutical  (XTEH:DFRB1) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Farabi Pharmaceutical Operating Margin % Related Terms


Farabi Pharmaceutical Operating Margin % Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical Operating Margin % Chart

Farabi Pharmaceutical Annual Data
Trend
Operating Margin %

Farabi Pharmaceutical Quarterly Data
Operating Margin %

XTEH:DFRB1 vs IMNPQ, INNV: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Farabi Pharmaceutical Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Farabi Pharmaceutical's Operating Margin % falls into.



Farabi Pharmaceutical Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Farabi Pharmaceutical's Operating Margin % for the fiscal year that ended in . 20 is calculated as

Operating Margin %=Operating Income (A: . 20 ) / Revenue (A: . 20 )
= /
= %

Farabi Pharmaceutical's Operating Margin % for the quarter that ended in . 20 is calculated as

Operating Margin %=Operating Income (Q: . 20 ) / Revenue (Q: . 20 )
= /
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a Operating Margin % of 0.00% as of . 20. Operating margin is the ratio of total operating income to net sales. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's Operating Margin % too high?
Farabi Pharmaceutical's current Operating Margin % is 0.00%.
How does Farabi Pharmaceutical's Operating Margin % compare to IMNPQ and INNV?
Farabi Pharmaceutical's Operating Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Farabi Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farabi Pharmaceutical's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Operating Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.